IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Caligan Partners LP

Q1 2025 Holdings

Filed 2025-05-15 | 16 holdings | $479.2M | 13F-HR | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
Liquidia Corporation(LQDA)COM NEW53635D202$119.7M8,118,59225.0%
Verona Pharma PLC(VRNA)SPONSORED ADS925050106$91.2M1,436,87819.0%
Exelixis Inc(EXEL)COM30161Q104$56.3M1,525,73011.8%
Mineralys Therapeutics Inc(MLYS)COM603170101$34.1M2,149,6677.1%
Evolus Inc(EOLS)COM30052C107$32.9M2,731,1546.9%
Sage Therapeutics Inc(SG7)COM78667J108$24.3M3,052,5385.1%
Biocryst Pharmaceuticals Inc(BCRX)COM09058V103$23.3M3,107,6694.9%
Anika Therapeutics Inc(ANIK)COM035255108$21.6M1,435,1304.5%
Agios Pharmaceuticals Inc(AGIO)COM00847X104$20.5M701,2804.3%
Revolution Medicines Inc(RVMD)COM76155X100$16.4M465,0003.4%
Merus N VCOMN5749R100$15.9M376,9543.3%
Y-Mabs Therapeutics Inc(YMABUSD)COM984241109$10.4M2,342,6092.2%
Abivax SA(ABVX)SPONSORED ADS00370M103$7.9M1,269,1191.7%
Verrica Pharmaceuticals IncCOM92511W108$4.0M8,992,9540.8%
Rezolute Inc(RZLT)COM NEW76200L309$409.8K141,3090.1%
Tyra Biosciences Inc(TYRA)COM90240B106$232.5K25,0000.0%